MedTrace Logo

TDF VS LAM + ADV in LAM + ADV Treated LAM-resistant CHB Patients With Undetectable Hepatitis B Virus DNA

NCT01732367 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 171

Last updated 2016-10-28

No results posted yet for this study

Summary

This study will provide a rationale for switch from lamivudine plus adefovir to tenofovir monotherapy in Lamivudine plus Adefovir Treated Lamivudine-resistant chronic hepatitis B patients with Undetectable Hepatitis B Virus DNA

Conditions

Interventions

DRUG

Lamivudine plus adefovir

Lamivudine 100mg QD for 96 weeks + Adefovir 10mg QD for 96 weeks

DRUG

Tenofovir

Tenofovir 300mg QD for 96 weeks

Sponsors & Collaborators

  • Kyungpook National University Hospital

    collaborator OTHER

  • Daegu Catholic University Medical Center

    collaborator OTHER

  • DongGuk University

    collaborator OTHER

  • Pusan National University Hospital

    collaborator OTHER

  • Yeungnam University Hospital

    collaborator OTHER

  • Keimyung University Dongsan Medical Center

    lead OTHER

Principal Investigators

  • Byoung Kuk Jang, M.D · Department of Internal Medicine, Keimyung University Dongsan Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2016-03-31
Completion
2016-04-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01732367 on ClinicalTrials.gov